It is now almost a decade since the first patient underwent catheter-based renal denervation as a participant in a safety and proof-of concept study (SYMPLICITY HTN-1). Since then, SYMPLICITY HTN-3 has indicated that renal denervation does not provide benefit for patients with resistant hypertension and the recently published SPYRAL HTN-OFF MED has shown that it does provide benefit for patients who are not receiving antihypertensive medication. In this commentary, Markus P Schlaich reviews the evidence for renal denervation.
BTG has highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th annual scientific sessions (14–17 June, New Orleans USA). The study found chronic deep vein thrombosis patients with post-thrombotic syndrome can be treated safely and effectively with Ekos therapy.
Adept Medical, the Auckland based manufacturer of the STARSystem, has announced the release of its latest product innovation, the I.R. Platform (interventional radiology platform). The I.R. Platform is an over-the-patient work surface, specifically designed for use by interventional radiologists when they are working through the femoral artery.
Argon Medical announced in June that it has formalised a Medical Advisory Board comprised of distinguished physicians from institutions across the USA who specialise in interventional medicine. The Medical Advisory Board will continue to provide scientific and clinical expertise to guide the organisation in planning and implementing product development initiatives and marketing programs with the goal of improving the lives of patients and their caregivers, a press release from the company states.
The ASTER randomised clinical trial that examined the effect of endovascular contact aspiration vs. stent retriever on revascularisation in patients with acute ischaemic stroke and large vessel occlusion in the anterior circulation found that first-line thrombectomy with contact aspiration compared with stent retriever did not result in an increased successful revascularisation rate at the end of the procedure.
Augmenix, a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy and interventional procedures, announced that the first patients have been treated with SpaceOAR hydrogel at the Chaim Sheba Medical Center in Tel Hashomer, Israel. SpaceOAR hydrogel is an absorbable prostate-rectum spacer that reduces rectal injury during prostate radiotherapy.
Avinger has announced positive two-year clinical data from the pivotal VISION study of the company’s Lumivascular technology. Twenty-four-month follow-up results from 89 patients were presented by Patrick Muck, chief of Vascular Surgery at Good Samaritan Hospital in Cincinnati, USA, at New Cardiovascular Horizons (NCVH) in New Orleans, USA. This includes an additional 34 patients beyond the interim data set presented on January 25, 2017.
Bard’s Lutonix 035 drug-coated balloon PTA catheter (DCB) has been granted premarket approval (PMA) by the US Food and Drug Administration (FDA) for a new indication and is now available for sale in the USA.
Biotronik has announced that 12-month data from the BIOFLEX-I study have demonstrated the safety and efficacy of the company’s Pulsar-18 self-expanding stent for blocked superficial femoral artery treatment.
BTG and the Society of Interventional Oncology (SIO) have expanded their commitment to the Immuno-oncology /interventional oncology research grant programme, by announcing a second round of funding available to investigators.
“As interventional radiology is established as a free standing specialty, an international outreach effort to establish guidelines for different interventional treatments is certainly needed,” Constantinos T Sofocleous, Memorial Sloan Kettering Cancer Center, New York, USA, and professor of Radiology, Weill Medical College of Cornell University, New York, tells Interventional News. Sofocleous is chair of the Scientific Programme Committee of World Conference on Interventional Oncology (WCIO) 2016.
A randomised, double-blind, placebo-controlled trial evaluating the efficacy of prophylactic dexamethasone in preventing the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma found it to be more effective than a placebo regimen.
While further refining where radioembolization should optimally lie in current treatment paradigms for the most common liver-confined or liver-dominant cancers is important, a honing of current administration protocols is also possible, writes Suvranu Ganguli, Boston, USA.
A retrospective review of single-institution experience, published in July in the Journal of Vascular and Interventional Radiology (JVIR), suggests that percutaneous image-guided ablation is feasible, well tolerated and achieves “acceptable” local tumour control rates.
The US FDA has approved the investigational device exemption (IDE) study to evaluate the safety and efficacy of IN.PACT AV access drug-coated balloon as a treatment for failing arteriovenous fistulas in end-stage renal disease patients.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos